Asia Pacific Glycomic Therapeutics Market Forecast to 2028

Report Code : BMIRE00027511 | Region : Asia Pacific | Industry : Pharmaceuticals | Published Date : 18/Nov/2022
Asia Pacific Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]

The glycomic therapeutics market in Asia Pacific is expected to grow from US$ 12,950.82 million in 2022 to US$ 34,592.83 million by 2028; it is estimated to grow at a CAGR of 17.8% from 2022 to 2028.

Wide Applications of Glycomics in Therapeutics to Provide Lucrative Opportunities for Market Growth

Glycomics is a novel method for creating medicines. It draws on the knowledge that glycans serve as the primary means of altering numerous molecules in biological systems. This alteration provides those molecules with their complete, functional form. Glycans are found in most top-selling biologics and half of the therapeutic proteins, including antibodies against COVID-19. Glycans of these proteins have been tailored to improve their effectiveness, lower the dosages required, and lessen negative effects. For instance, understanding the biological functions of glycans has led to their inclusion as essential ingredients in medications for the treatment of diabetes, the prevention of blood clotting, and the improvement of in vitro fertilization. Changes in the glycans on a microbe's surface are frequently connected to the microorganisms' resistance to popular medications. This property is used for detecting particular glycans in infection samples, disabling the protective biofilms formed by the infecting bacteria, and weakening the glycan-rich cell walls of microorganisms. More than 130 uncommon genetic illnesses, many of which are fatal in childhood, are brought on by errors. Understanding the glycans responsible for a few of these problems has helped develop therapies. Since glycans can play a crucial role in studying attacks of bacteria and viruses on the immune systems of humans, they are employed in vaccinations. Additionally, recent research on SARS-CoV-2, which causes COVID-19, has shown infection pathways that depend on the virus's usage of human glycans. Glycomics has the potential to bring new perspectives to precision medicine, which is currently dominated by genetic and proteomic tools. Therefore, the high adoption of glycomics in various therapeutic areas would propel the demand for these techniques in the coming years. Nonetheless, ongoing research and developments and clinical advancements in the field of therapeutics are expected to create lucrative growth opportunities for the glycomics therapeutics market during the forecast period.

Market Overview

Asia Pacific (APAC) is the fastest-growing market for glycomic therapeutics. The Asia Pacific glycomics therapeutics market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. Asia Pacific is likely to account for ~11.89% share of the global glycomic therapeutics market in 2022 owing to the improving government support in countries, collaboration of research organizations, rising glycomics research institutes, and advancing healthcare infrastructure. Therefore, the region offers several opportunities for the glycomic therapeutics market players to grow during the forecast period.

Asia Pacific Glycomic Therapeutics Market Revenue and Forecast to 2028 (US$ Billion)

Asia Pacific Glycomic Therapeutics Market Segmentation

The Asia Pacific glycomic therapeutics market is segmented on the basis of class, structure, indications, mode of action, and country.

Based on class, the Asia Pacific glycomic therapeutics market is bifurcated into isolated and synthetic. The synthetic segment registered a larger market share in 2022. Based on structure, the Asia Pacific glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. The glycoproteins segment held the largest market share in 2022. Based on indications, the Asia Pacific glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anaemia, anti-adhesive & anti-inflammatory, cataracts, gaucher’s disease, MPS-1 & IV, cancer, alzheimer’s disease, influenza type A & B, and others. The influenza type a & b segment held the largest market share in 2022. Based on mode of action, the Asia Pacific glycomic therapeutics market is segmented into inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin & enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1 and 2 and 3, beta & gamma interferons, and others. The erythropoietin & enzyme replacement therapy (ERT) segment held the largest market share in 2022. Based on country, the Asia Pacific glycomic therapeutics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the market in 2022. BioMarin Pharmaceutical Inc.; Genzyme Corporation (Sanofi); Bayer AG; Alzheon, Inc.; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Ltd. are the leading companies operating in the glycomic therapeutics market in Asia Pacific.

The List of Companies - Asia Pacific Glycomic Therapeutics Market

● BioMarin Pharmaceutical Inc.                    

● Genzyme Corporation (Sanofi)                 

● Bayer AG                                                            

● GlaxoSmithKline plc.         

● F. Hoffmann-La Roche Ltd

TABLE OF CONTENTS

1. Introduction

1.1 Study Scope

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Asia Pacific Glycomic Therapeutics Market – By Class

1.3.2 Asia Pacific Glycomic Therapeutics Market – By Structures

1.3.3 Asia Pacific Glycomic Therapeutics Market – By Indications

1.3.4 Asia Pacific Glycomic Therapeutics Market – By Mode of Action

1.3.5 Asia Pacific Glycomic Therapeutics Market – By Country

2. Asia Pacific Glycomic Therapeutics Market– Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Asia Pacific Glycomic Therapeutics Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 Asia Pacific – PEST Analysis

4.3 Expert Opinion

5. Asia Pacific Glycomic Therapeutics Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Wide Application in Various Disorders Followed by the Development of New Treatment Processes

5.1.2 Increasing Research and Development In the Field of Glycomic Therapeutics

5.2 Market Restraints

5.2.1 Shortage of Skilled Professionals and Lack of Research & Development laboratories in Developing Countries.

5.3 Market Opportunities

5.3.1 Wide Applications of Glycomics in Therapeutics

5.4 Future Trends

5.4.1 New Tools in Glycomics Research

5.5 Impact Analysis

6. Glycomic Therapeutics Market– Asia Pacific Analysis

6.1 Asia Pacific Glycomic Therapeutics Market Revenue Forecast and Analysis

6.1.1 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, (US$ Million)

7. Asia Pacific Glycomic Therapeutics Market Revenue and Forecast to 2028– by Class

7.1 Overview

7.2 Asia Pacific Glycomic Therapeutics Market, By Class 2022 & 2028 (%)

7.2.1 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)

7.3 Isolated

7.3.1 Overview

7.3.2 Asia Pacific Isolated Revenue and Forecast to 2028 (US$ Million)

7.4 Synthetic

7.4.1 Overview

7.4.2 Asia Pacific Synthetic - Revenue and Forecast to 2028 (US$ Million)

8. Asia Pacific Glycomics Therapeutics Market Analysis and Forecasts To 2028 – By Indication

8.1 Overview

8.2 Asia Pacific Glycomics Market, By Indication 2022 & 2028 (%)

8.2.1 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

8.3 Thrombosis and Chemoprophylaxis

8.3.1 Overview

8.3.2 Asia Pacific Thrombosis and chemoprophylaxis Revenue and Forecast to 2028 (US$ Million)

8.4 Anaemia

8.4.1 Overview

8.4.2 Asia Pacific Anaemia Revenue and Forecast to 2028 (US$ Million)

8.5 Anti-adhesive and Anti-inflammatory

8.5.1 Overview

8.5.2 Asia Pacific Anti-adhesive and Anti-inflammatory Revenue and Forecast to 2028 (US$ Million)

8.6 Cataract

8.6.1 Overview

8.6.2 Asia Pacific Cataract Revenue and Forecast to 2028 (US$ Million)

8.7 Gaucher’s diseases

8.7.1 Overview

8.7.2 Asia Pacific Gaucher’s diseases Revenue and Forecast to 2028 (US$ Million)

8.8 MPS-1 & IV

8.8.1 Overview

8.8.2 Asia Pacific MPS-1 & IV Revenue and Forecast to 2028 (US$ Million)

8.9 Cancer

8.9.1 Overview

8.9.2 Asia Pacific Cancer Revenue and Forecast to 2028 (US$ Million)

8.10 Alzheimer's

8.10.1 Overview

8.10.2 Asia Pacific Alzheimer's Revenue and Forecast to 2028 (US$ Million)

8.11 Influenza Type A and B

8.11.1 Overview

8.11.2 Asia Pacific Influenza Type A and B Revenue and Forecast to 2028 (US$ Million)

8.12 Others

8.12.1 Overview

8.12.2 Asia Pacific Others Revenue and Forecast to 2028 (US$ Million)

9. Asia Pacific Glycomic Therapeutics Market Revenue and Forecast to 2028 – by Structures

9.1 Overview

9.2 Asia Pacific Glycomic Therapeutics Market, By Structures 2022 & 2028 (%)

9.2.1 Asia Pacific: Glycomic Therapeutics Market, by Structures, 2019–2028 (US$ Million)

9.2.1.1 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

9.2.1.2 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

9.2.1.3 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

9.2.1.4 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

9.3 Glycoproteins

9.3.1 Overview

9.3.2 Asia Pacific Glycoproteins - Market Revenue and Forecast to 2028 (US$ Million)

9.4 Targeting Sialic Acid

9.4.1 Overview

9.4.2 Asia Pacific Targeting Sialic Acid - Market Revenue and Forecast to 2028 (US$ Million)

9.4.3 Zanamivir

9.4.3.1 Overview

9.4.3.2 Asia Pacific Zanamivir - Market Revenue and Forecast to 2028 (US$ Million)

9.4.4 Oseltamivir

9.4.4.1 Overview

9.4.4.2 Asia Pacific Oseltamivir - Market Revenue and Forecast to 2028 (US$ Million)

9.5 Proteoglycans

9.5.1 Overview

9.5.2 Asia Pacific Proteoglycans - Market Revenue and Forecast to 2028 (US$ Million)

9.6 Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans

9.6.1 Overview

9.6.2 Asia Pacific Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans - Market Revenue and Forecast to 2028 (US$ Million)

9.7 Targeting Glycosaminoglycans

9.7.1 Overview

9.7.2 Asia Pacific Targeting Glycosaminoglycans - Market Revenue and Forecast to 2028 (US$ Million)

9.7.3 Heparin

9.7.3.1 Overview

9.7.3.2 Asia Pacific Heparin - Market Revenue and Forecast to 2028 (US$ Million)

9.7.4 Hyaluronan (HA)

9.7.4.1 Overview

9.7.4.2 Asia Pacific Hyaluronan (HA)- Market Revenue and Forecast to 2028 (US$ Million)

9.7.5 Laronidase

9.7.5.1 Overview

9.7.5.2 Asia Pacific Laronidase - Market Revenue and Forecast to 2028 (US$ Million)

9.7.6 Galsulfase (Naglazyme)

9.7.6.1 Overview

9.7.6.2 Asia Pacific Galsulfase (Naglazyme) - Market Revenue and Forecast to 2028 (US$ Million)

9.7.7 Hyaluronidase (Cumulase)

9.7.7.1 Overview

9.7.7.2 Asia Pacific Hyaluronidase (Cumulase) - Market Revenue and Forecast to 2028 (US$ Million)

9.7.8 Others

9.7.8.1 Overview

9.7.8.2 Asia Pacific Others - Market Revenue and Forecast to 2028 (US$ Million)

9.8 Targeting Glycosphingolipids

9.8.1 Overview

9.8.2 Asia Pacific Targeting Glycosphingolipids - Market Revenue and Forecast to 2028 (US$ Million)

9.8.3 Imiglucerase (Cerezyme)

9.8.3.1 Overview

9.8.3.2 Asia Pacific Imiglucerase (Cerezyme)- Market Revenue and Forecast to 2028 (US$ Million)

9.8.3.3 Agalsidase (Fabrazyme)

9.8.3.3.1 Overview

9.8.3.3.2 Asia Pacific Agalsidase (Fabrazyme) - Market Revenue and Forecast to 2028 (US$ Million)

9.8.3.4 N-butyl-deoxynojirimycin (DNJ)

9.8.3.4.1 Overview

9.8.3.4.2 Asia Pacific N-butyl-deoxynojirimycin (DNJ) - Market Revenue and Forecast to 2028 (US$ Million)

9.8.4 Others

9.8.4.1 Overview

9.8.4.2 Asia Pacific Others - Market Revenue and Forecast to 2028 (US$ Million)

9.9 Others

9.9.1 Overview

9.9.2 Asia Pacific Others - Market Revenue and Forecast to 2028 (US$ Million)

9.9.3 Acarbose

9.9.3.1 Overview

9.9.3.2 Asia Pacific Acarbose - Market Revenue and Forecast to 2028 (US$ Million)

9.9.3.3 Alglucosidase Alfa (Myozyme)

9.9.3.3.1 Overview

9.9.3.3.2 Asia Pacific Alglucosidase Alfa (Myozyme) - Market Revenue and Forecast to 2028 (US$ Million)

9.9.3.4 Allosamidin

9.9.3.4.1 Overview

9.9.3.4.2 Asia Pacific Allosamidin - Market Revenue and Forecast to 2028 (US$ Million)

9.9.4 Others

9.9.4.1 Overview

9.9.4.2 Asia Pacific Others - Market Revenue and Forecast to 2028 (US$ Million)

10. Asia Pacific Glycomic Therapeutics Market Revenue and Forecast to 2028 – by Mode of Action

10.1 Overview

10.2 Asia Pacific Glycomic Therapeutics Market, By Mode of Action 2022 & 2028 (%)

10.2.1 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

10.3 Inhibits Neuraminidase

10.3.1 Overview

10.3.2 Asia Pacific Inhibits Neuraminidase - Market Revenue and Forecast to 2028 (US$ Million)

10.4 Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate

10.4.1 Overview

10.4.2 Asia Pacific Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate - Market Revenue and Forecast to 2028 (US$ Million)

10.5 Erythropoietin And Enzyme Replacement Therapy (ERT)

10.5.1 Overview

10.5.2 Asia Pacific Erythropoietin And Enzyme Replacement Therapy (ERT) - Market Revenue and Forecast to 2028 (US$ Million)

10.6 Tissue Plasminogen Activator

10.6.1 Overview

10.6.2 Asia Pacific Tissue Plasminogen Activator - Market Revenue And Forecasts To 2028 (US$ Million)

10.7 Inhibits Glucosylceramide Synthase

10.7.1 Overview

10.7.2 Asia Pacific Inhibits Glucosylceramide Synthase - Market Revenue And Forecasts To 2028 (US$ Million)

10.8 Interleukin 1 And 2 And 3

10.8.1 Overview

10.8.2 Asia Pacific Interleukin 1 And 2 And 3- Market Revenue And Forecasts To 2028 (US$ Million)

10.9 Beta And Gamma Interferons

10.9.1 Overview

10.9.2 Asia Pacific Beta And Gamma Interferons- Market Revenue And Forecasts To 2028 (US$ Million)

10.10 Others

10.10.1 Overview

10.10.2 Asia Pacific Others- Market Revenue And Forecasts To 2028 (US$ Million)

11. Asia Pacific Glycomic Therapeutics Market Revenue and Forecasts to 2028 – Country Analysis

11.1 Asia Pacific Glycomic Therapeutics Market Revenue and Forecasts To 2028

11.1.1 Overview

11.1.2 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Country (%)

11.1.2.1 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.1.2.1.1 Overview

11.1.2.1.2 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.1.2.1.3 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)

11.1.2.1.4 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019–2028 (US$ Million)

11.1.2.1.4.1 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

11.1.2.1.4.2 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

11.1.2.1.4.3 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

11.1.2.1.4.4 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

11.1.2.1.5 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

11.1.2.1.6 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

11.1.2.2 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.1.2.2.1 Overview

11.1.2.2.2 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.1.2.2.3 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)

11.1.2.2.4 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019–2028 (US$ Million)

11.1.2.2.4.1 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

11.1.2.2.4.2 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

11.1.2.2.4.3 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

11.1.2.2.4.4 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

11.1.2.2.5 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

11.1.2.2.6 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

11.1.2.3 India Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.1.2.3.1 Overview

11.1.2.3.2 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.1.2.3.3 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)

11.1.2.3.4 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019–2028 (US$ Million)

11.1.2.3.4.1 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

11.1.2.3.4.2 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

11.1.2.3.4.3 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

11.1.2.3.4.4 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

11.1.2.3.5 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

11.1.2.3.6 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

11.1.2.4 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.1.2.4.1 Overview

11.1.2.4.2 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.1.2.4.3 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)

11.1.2.4.4 South Korea: Glycomic Therapeutics Market, by Structures, 2019–2028 (US$ Million)

11.1.2.4.4.1 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

11.1.2.4.4.2 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

11.1.2.4.4.3 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

11.1.2.4.4.4 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

11.1.2.4.5 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

11.1.2.4.6 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

11.1.2.5 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.1.2.5.1 Overview

11.1.2.5.2 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)

11.1.2.5.3 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)

11.1.2.5.4 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019–2028 (US$ Million)

11.1.2.5.4.1 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

11.1.2.5.4.2 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

11.1.2.5.4.3 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

11.1.2.5.4.4 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

11.1.2.5.5 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

11.1.2.5.6 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

11.1.2.6 Rest of Asia Pacific: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.2.6.1 Overview

11.1.2.6.2 Rest of Asia Pacific: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.2.6.3 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)

11.1.2.6.4 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019–2028 (US$ Million)

11.1.2.6.4.1 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

11.1.2.6.4.2 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

11.1.2.6.4.3 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

11.1.2.6.4.4 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

11.1.2.6.5 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

11.1.2.6.6 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

12. Glycomic Therapeutics Market –Industry Landscape

12.1 Overview

12.2 Growth Strategies in the Glycomic Therapeutics Market (%)

12.3 Organic Developments

12.3.1 Overview

12.4 Inorganic Developments

12.4.1 Overview

13. Company Profiles

13.1 BioMarin Pharmaceutical Inc.

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Genzyme Corporation (Sanofi)

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 Bayer AG

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 GlaxoSmithKline plc.

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 F. Hoffmann-La Roche Ltd

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms in Glycomic Therapeutics Market

LIST OF TABLES.

Table 1. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, (US$ Million).

Table 2. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million).

Table 3. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

Table 4. Asia Pacific: Glycomic Therapeutics Market, by Structures – Revenue and Forecast to 2028 (US$ Million)

Table 5. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

Table 6. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

Table 7. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

Table 8. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

Table 9. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

Table 10. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million).

Table 11. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures – Revenue and Forecast to 2028 (US$ Million)

Table 12. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

Table 13. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

Table 14. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

Table 15. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

Table 16. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

Table 17. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

Table 18. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million).

Table 19. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures – Revenue and Forecast to 2028 (US$ Million)

Table 20. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

Table 21. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

Table 22. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

Table 23. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

Table 24. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

Table 25. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

Table 26. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million).

Table 27. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures – Revenue and Forecast to 2028 (US$ Million)

Table 28. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

Table 29. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

Table 30. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

Table 31. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

Table 32. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

Table 33. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

Table 34. South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million).

Table 35. South Korea: Glycomic Therapeutics Market, by Structures – Revenue and Forecast to 2028 (US$ Million)

Table 36. South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

Table 37. South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

Table 38. South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

Table 39. South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

Table 40. South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

Table 41. South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

Table 42. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million).

Table 43. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures – Revenue and Forecast to 2028 (US$ Million)

Table 44. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

Table 45. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

Table 46. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

Table 47. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

Table 48. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

Table 49. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

Table 50. Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million).

Table 51. Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures – Revenue and Forecast to 2028 (US$ Million)

Table 52. Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)

Table 53. Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)

Table 54. Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)

Table 55. Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)

Table 56. Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)

Table 57. Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)

Table 58. Organic Developments in the Glycomic Therapeutics Market

Table 59. Inorganic Developments in the Glycomic Therapeutics Market

Table 60. Glossary of Terms in Glycomic Therapeutics Market

The List of Companies - Asia Pacific Glycomic Therapeutics Market

● BioMarin Pharmaceutical Inc.                    

● Genzyme Corporation (Sanofi)                 

● Bayer AG                                                            

● GlaxoSmithKline plc.         

● F. Hoffmann-La Roche Ltd

Reason To Buy

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific Glycomic Therapeutics Market.

● Highlights key business priorities in order to assist companies to realign their business strategies.

● The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific Glycomic Therapeutics Market, thereby allowing players across the value chain to develop effective long-term strategies.

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

● Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.

● Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

AVAILABLE CUSTOMIZATION RESEARCH METHODOLOGY REQUEST FOR TOC FREE SAMPLE REPORT
CHOOSE LICENCE TYPE
(Asia Pacific Glycomic Therapeutics Market Forecast to 2028)
  • Single User Price $3,000$2,400
  • Site Price $4,000$3,200
  • Enterprise Price $5,000$4,000
Buy Now Add to Cart
REQUEST FOR TOC
SPEAK TO ANALYST
FREE SAMPLE
REPORT
INQUIRE BEFORE
BUYING
TOP
Quick Enquiry